Replimune Group, Inc. (FRA:7R8)

Market Cap	464.16M -40.4%
Revenue (ttm)	n/a
Net Income	-264.44M
EPS	-2.96
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	260
Open	6.15
Previous Close	6.45
Day's Range	6.15 - 6.15
52-Week Range	2.30 - 13.90
Beta	n/a
RSI	38.52
Earnings Date	Feb 6, 2026

About Replimune Group

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 479
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7R8

Financial Performance

Financial numbers in USD